News from kazia therapeutics limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 10, 2020, 10:00 ET Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has...


Sep 22, 2020, 10:00 ET Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered ...


Apr 07, 2020, 08:00 ET Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data...


Nov 25, 2019, 10:00 ET Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim ...


Jul 17, 2019, 08:00 ET Kazia calls for greater awareness of the deadliest brain cancer in the US

This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater...


May 20, 2019, 08:00 ET Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered ...


May 08, 2019, 08:00 ET Kazia calls for greater awareness of the deadliest gynecological cancer in the US

This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater...


Apr 01, 2019, 09:00 ET Kazia Presents Positive Cantrixil Phase I Data at AACR Conference

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a...


Oct 29, 2018, 06:00 ET Progress Update on GDC-0084 Program

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an update to...


Oct 22, 2018, 06:00 ET Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer

The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre...


Oct 10, 2018, 10:00 ET Cantrixil Phase I Study Progresses To Next Stage

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the successful...


Jun 19, 2018, 06:00 ET Kazia Releases Preliminary Cantrixil Phase I Data

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to ...


Mar 29, 2018, 08:29 ET Commencement de l'étude clinique en phase II du GDC-0084

Kazia Therapeutics Limited (ASX : KZA ; NASDAQ : KZIA), société australienne de développement de médicaments oncologiques, a le plaisir d'annoncer le ...


Mar 29, 2018, 03:21 ET Start der klinischen Phase-II-Studie von GDC-0084

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA), ein australisches Unternehmen zur Entwicklung onkologischer Medikamente, meldet den Beginn einer ...


Mar 28, 2018, 07:57 ET Commencement Of Phase II Clinical Study Of GDC-0084

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology drug development company, is pleased to announce commencement of an...


Feb 24, 2018, 03:13 ET Kazie recibe de la FDA la designación de medicamento huérfano para el GDC-0084

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA), empresa biotecnológica australiana dedicada al ámbito de la oncología, se complace en anunciar...


Feb 24, 2018, 03:07 ET Kazia erhält Orphan-Kennzeichnung der FDA für GDC-0084

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), ein australisches Biotechnologie-Unternehmen mit Schwerpunkt auf Onkologie, freut sich, bekannt...


Feb 23, 2018, 09:00 ET Kazia Receives FDA Orphan Designation for GDC-0084

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United...


Feb 23, 2018, 01:35 ET Kazia reçoit la désignation de médicament orphelin de la FDA pour le GDC-0084

Kazia Therapeutics Limited (ASX : KZA ; NASDAQ : KZIA), une société australienne de biotechnologie se consacrant à l'oncologie, est heureuse...